Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Can-Fite BioPharma Ltd. < Previous 1 2 3 Next > Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis September 24, 2024 From Can-Fite BioPharma Ltd. Via GlobeNewswire Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health September 16, 2024 From Can-Fite BioPharma Ltd. Via GlobeNewswire Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds August 08, 2024 From Can-Fite BioPharma Ltd. Via GlobeNewswire Can-Fite Provides Namodenoson Patent Update July 29, 2024 From Can-Fite BioPharma Ltd. Via GlobeNewswire Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8 July 17, 2024 From Can-Fite BioPharma Ltd. Via GlobeNewswire Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer July 11, 2024 From Can-Fite BioPharma Ltd. Via GlobeNewswire Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson July 01, 2024 From Can-Fite BioPharma Ltd. Via GlobeNewswire Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix June 28, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver June 24, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study June 10, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study June 05, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases May 29, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 May 27, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6 May 23, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study May 13, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study May 09, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 May 06, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal April 25, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH April 15, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients April 03, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite Reports 2023 Financial Results and Clinical Update March 28, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference March 11, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada February 28, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication January 30, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study January 29, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies December 20, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan December 18, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development December 04, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update November 30, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Tickers CANF Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds November 21, 2023 From Can-Fite BioPharma Ltd. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.